title: Long-term oral lacosamide in painful diabetic neuropathy: a two-year open-label extension trial.
abstract: OBJECTIVE
  This open-label follow-on trial aimed to investigate long-term safety and efficacy of lacosamide in patients with painful diabetic neuropathy.
  
  
  METHODS
  After 1-week baseline period, lacosamide 100mg/day was started. Each week, based on pain and safety assessments, doses were escalated by 100mg/day to an optimal level, up to a maximum of 400mg/day. Patients then entered the 20-week maintenance period (dose adjusted as needed). Thereafter, patients could opt to continue lacosamide up to about 2.5 years (extension period).
  
  
  RESULTS
  Of the 69 enrolled patients, 47 (68%) completed the 20-week maintenance period and elected to continue into the extension period; 37/69 (54%) patients were in the extension period for more than one year and 34/69 (49%) continued until study termination. The modal lacosamide dose in most patients (54%) was 400mg/day. Headache, upper respiratory tract infection, arthralgia, sinusitis, nasopharyngitis, and back pain were the most frequently reported adverse events (10% of patients). Significant reductions from baseline in Likert pain scores began during dose titration and were sustained throughout the study. Significant improvements were also seen in Neuropathic Pain Scale, Quality of Life scores, and Patient's Global Impression of Change assessment. Of 34 patients at study termination, 32 (90%) elected to continue with lacosamide treatment in another long-term open-label trial (NCT00235443).
  
  
  CONCLUSIONS
  The long-term safety profile and sustained efficacy of lacosamide observed in this trial support its continued development for treatment of painful diabetic neuropathy.
authors.affiliation: Nerve and Muscle Center of Texas, 6624 Fannin Suite 1670, Houston, TX 77030, USA. Nerveandmuscle@houston.rr.com
authors.forename: Aziz
authors.initials: A
authors.lastname: Shaibani
authors.forename: Victor
authors.initials: V
authors.lastname: Biton
authors.forename: Richard
authors.initials: R
authors.lastname: Rauck
authors.forename: Brigitte
authors.initials: B
authors.lastname: Koch
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Simpson
mesh_terms: D000081:Acetamides / Q000008:administration & dosage* / Q000009:adverse effects; D000284:Administration, Oral; D000368:Aged; D000700:Analgesics / Q000008:administration & dosage / Q000009:adverse effects; D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects; D003929:Diabetic Neuropathies / Q000188:drug therapy* / Q000503:physiopathology; D004244:Dizziness / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D000078334:Lacosamide; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010147:Pain Measurement / Q000379:methods; D017060:Patient Satisfaction; D010525:Peripheral Nerves / Q000187:drug effects / Q000503:physiopathology; D011788:Quality of Life; D020521:Stroke / Q000139:chemically induced; D013995:Time; D016896:Treatment Outcome
chemical_list: D000081:Acetamides; D000700:Analgesics; D000927:Anticonvulsants; D000078334:Lacosamide